| Not Yet Recruiting | A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian C NCT07286266 | GlaxoSmithKline | Phase 3 |
| Recruiting | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558 | Merck Sharp & Dohme LLC | Phase 3 |
| Not Yet Recruiting | DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Y NCT07440290 | Cancer Research UK | Phase 2 / Phase 3 |
| Recruiting | Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions NCT07280312 | Mayo Clinic | N/A |
| Not Yet Recruiting | Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) NCT07273396 | Seoul National University Hospital | Phase 1 / Phase 2 |
| Recruiting | Validation of the Sentinel Lymph Node Technique in Early-stage Ovarian Cancer (SENTOV II) NCT06963268 | Instituto de Investigacion Sanitaria La Fe | Phase 3 |
| Recruiting | A Study of LY4337713 in Participants With FAP-Positive Solid Tumors NCT07213791 | Eli Lilly and Company | Phase 1 |
| Recruiting | A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) NCT07213804 | Eli Lilly and Company | Phase 3 |
| Active Not Recruiting | A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations NCT07038369 | Atavistik Bio, Inc | Phase 1 |
| Recruiting | Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumo NCT06885697 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Centralization and Oncologic Outcomes in Ovarian Cancer NCT07075939 | Azienda USL Reggio Emilia - IRCCS | — |
| Not Yet Recruiting | A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epi NCT06887933 | GlaxoSmithKline | Phase 4 |
| Not Yet Recruiting | BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer NCT06620029 | BioMimetix JV, LLC | Phase 1 / Phase 2 |
| Recruiting | Ultrasound-guided Transvaginal Aspiration of Cystic Pelvic Lesions NCT06988280 | Universitaire Ziekenhuizen KU Leuven | — |
| Recruiting | A Study of DM002 in Patients With Advanced Solid Tumors NCT06751329 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd. | Phase 1 |
| Recruiting | Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovar NCT06543537 | Dana-Farber Cancer Institute | N/A |
| Recruiting | OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study NCT06611072 | Gynaecologisch Oncologisch Centrum Zuid | N/A |
| Recruiting | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors NCT06819215 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Recruiting | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 | NiKang Therapeutics, Inc. | Phase 1 |
| Recruiting | A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women with an Ovarian Mass NCT06566716 | Cleo Diagnostics Ltd | — |
| Recruiting | Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Se NCT07035587 | Yonsei University | — |
| Active Not Recruiting | A Study of SGN-MesoC2 in Advanced Solid Tumors NCT06466187 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Not Yet Recruiting | Research and Application of Ultrasonic Intelligent Diagnosis System for Ovarian Mass NCT06528236 | Zhejiang Provincial People's Hospital | — |
| Recruiting | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer NCT06380816 | Cancer Research UK | Phase 1 / Phase 2 |
| Recruiting | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors NCT06400472 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | SerUm and Plasma MicroRNAs in Malignant Ovarian gERm Cell Tumours NCT06329323 | Imperial College London | — |
| Recruiting | A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With So NCT06051695 | A2 Biotherapeutics Inc. | Phase 1 / Phase 2 |
| Terminated | A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors NCT06264921 | NiKang Therapeutics, Inc. | Phase 1 |
| Not Yet Recruiting | The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer NCT06242392 | Fujian Cancer Hospital | — |
| Recruiting | A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy NCT06023862 | Yonsei University | Phase 2 |
| Recruiting | A Cohort Study of Hereditary Ovarian Cancer Risk Prediction Models and Pathogenesis Exploration NCT06564428 | Peking University Third Hospital | — |
| Active Not Recruiting | A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 NCT06003231 | Seagen, a wholly owned subsidiary of Pfizer | Phase 2 |
| Recruiting | Adebrelimab Combined With Fuzuloparib in the Treatment of Patients With Recurrent Platinum-resistant Ovarian C NCT05753826 | Fujian Cancer Hospital | Phase 2 |
| Completed | Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations NCT05904730 | Lynkcell Europe | Phase 1 |
| Terminated | Study of RO7515629 in Participants With HLA-G Positive Solid Tumors NCT05769959 | Hoffmann-La Roche | Phase 1 |
| Recruiting | DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/ NCT05786716 | Cancer Research UK | Phase 2 / Phase 3 |
| Completed | Additive Role of ADC Value to ORADS in Adnexal Lesions NCT07202429 | Cairo University | — |
| Unknown | MRI in Ovarian Tumors NCT05769205 | Assiut University | N/A |
| Recruiting | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Posi NCT05768178 | Cancer Research UK | Phase 2 / Phase 3 |
| Active Not Recruiting | AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Can NCT05617755 | Arsenal Biosciences, Inc. | Phase 1 |
| Recruiting | Prospective Study of Detection of Sarcopenia in Clinical Practice for Patient With Ovarian or Endometrial Canc NCT05833321 | Centre Hospitalier Metropole Savoie | N/A |
| Active Not Recruiting | Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colo NCT05185947 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer NCT05261490 | Pfizer | Phase 1 / Phase 2 |
| Recruiting | Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker NCT05763511 | University of Aarhus | — |
| Active Not Recruiting | A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer NCT05451849 | TCR2 Therapeutics | Phase 1 / Phase 2 |
| Unknown | First-line Olaparib Combined With Bevacizumab Maintenance Therapy NCT05440578 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Recruiting | Laparoscopic Interval Cytoreductive Surgery in Advance Ovarian Cancer NCT06883409 | Instituto Nacional de Cancerologia de Mexico | N/A |
| Terminated | A Study of SGN-ALPV in Advanced Solid Tumors NCT05229900 | Seagen Inc. | Phase 1 |
| Terminated | A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participan NCT06964165 | Tesaro, Inc. | Phase 2 |
| Unknown | Outcomes of First-line Olaparib Mono-maintenance therapy-a Multicenter, Retrospective Study Using Data From Re NCT05153603 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | — |
| Unknown | The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening NCT05290961 | Chongqing University Cancer Hospital | — |
| Recruiting | Retrospective Study of Brachytherapy NCT05242861 | Zhejiang Cancer Hospital | — |
| Unknown | Treat of Functional Ovarian Cysts by Compare Between Cocs and Progesterone Only Pills NCT05244811 | Sohag University | Phase 3 |
| Terminated | A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors NCT05194072 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | IOTA Ultrasound Criteria and Serum CA 125 for Ovarian Malignancy Detection NCT06977334 | Maharajgunj Medical Campus | — |
| Terminated | The Possible Influence of Different Follow-up Modalities on Overall Survival in Ovarian Cancer NCT05352217 | Stiftung Swiss Tumor Institute | — |
| Recruiting | Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing NCT04981119 | A2 Biotherapeutics Inc. | — |
| Terminated | A Study of PF-07260437 in Advanced or Metastatic Solid Tumors NCT05067972 | Pfizer | Phase 1 |
| Completed | MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) NCT05007106 | Merck Sharp & Dohme LLC | Phase 2 |
| Terminated | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) NCT05001282 | Elucida Oncology | Phase 1 / Phase 2 |
| Active Not Recruiting | Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cance NCT04807166 | Wenjun Cheng | Phase 2 |
| Recruiting | Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) NCT04956640 | Eli Lilly and Company | Phase 1 / Phase 2 |
| Completed | Spectroscopy in Ovarian Cancer NCT04817449 | University of Exeter | — |
| Terminated | A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer NCT04999605 | Akeso | Phase 1 / Phase 2 |
| Recruiting | A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advan NCT04895709 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Terminated | A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic NCT04644315 | Hoffmann-La Roche | Phase 2 |
| Recruiting | Improved Diagnosis of Ovarian Cancer NCT05842629 | University of Aarhus | — |
| Recruiting | Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. NCT05610501 | Universitaire Ziekenhuizen KU Leuven | — |
| Recruiting | A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESAR NCT04641247 | GlaxoSmithKline | Phase 2 |
| Unknown | Liquid Biopsies for Improving the Pre-operative Diagnosis of Ovarian Cancer NCT04971421 | The Netherlands Cancer Institute | — |
| Recruiting | Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer NCT04519151 | Sheba Medical Center | Phase 2 |
| Completed | Study of AK112 in the Treatment of Advanced Gynecological Tumors NCT04870177 | Akeso | Phase 2 |
| Completed | Efficacy and Safety of SBRT in Oligo-metastatic/Persistent/Recurrent Ovarian Cancer NCT04593381 | Gemelli Molise Hospital | N/A |
| Terminated | A Study of Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-grade Serous Ovarian Cancer (HGSOC) Part NCT04893551 | BerGenBio ASA | Phase 1 |
| Active Not Recruiting | CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors NCT04660929 | Carisma Therapeutics Inc | Phase 1 |
| Terminated | A Study of SGN-STNV in Advanced Solid Tumors NCT04665921 | Seagen Inc. | Phase 1 |
| Unknown | Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian NCT04556071 | Xiaoxiang Chen | Phase 2 |
| Withdrawn | To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resis NCT04561817 | Icahn School of Medicine at Mount Sinai | Phase 2 |
| Active Not Recruiting | Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal De NCT04498117 | CanariaBio Inc. | Phase 3 |
| Completed | An INternational Frontline Ovarian Cancer Real World Management Study NCT04460768 | AstraZeneca | — |
| Recruiting | A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632 | Seagen, a wholly owned subsidiary of Pfizer | Phase 1 |
| Completed | Impact of the COVID-19 Pandemic in Gynecological Oncology NCT04351139 | Hospices Civils de Lyon | — |
| Recruiting | Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer NCT04794322 | Massachusetts General Hospital | — |
| Completed | Characterizing the Cross-sectional Approach to Investigate the Prevalence of Tissue BRCA1/2 Mutations in Newly NCT04222465 | AstraZeneca | — |
| Completed | A Study for Post-Marketing Surveillance of Niraparib in the Treatment of Adult Participants for Approved Indic NCT04589039 | Takeda | — |
| Completed | Diagnosing Ovarian Cysts - the DOC Study NCT04188652 | Rigshospitalet, Denmark | — |
| Completed | Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors. NCT04283773 | Assiut University | — |
| Completed | Cancer Loyalty Card Study NCT03994653 | Imperial College London | — |
| Terminated | Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Partici NCT03955471 | Tesaro, Inc. | Phase 2 |
| Unknown | Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) NCT04055038 | Blokhin's Russian Cancer Research Center | Phase 2 / Phase 3 |
| Unknown | Ovarium Cancer Detection by TEP's and ctDNA NCT04022863 | Gynaecologisch Oncologisch Centrum Zuid | — |
| Completed | Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study NCT05734911 | Zhongda Hospital | — |
| Completed | An Interventional Study of Avastin (Bevacizumab) in Patients With Advanced/Metastatic Epithelial Ovarian Cance NCT01932125 | Hoffmann-La Roche | Phase 4 |
| Completed | A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cance NCT03574779 | Tesaro, Inc. | Phase 2 |
| Active Not Recruiting | A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based NCT03602859 | Tesaro, Inc. | Phase 3 |
| Completed | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (o NCT03648489 | Imperial College London | Phase 2 |
| Completed | Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of M NCT03593681 | Boston Scientific Corporation | — |
| Completed | Gynacological Imaging Reporting and Data System in Ovarian Masses by Ultrasonography NCT03175991 | Assiut University | — |
| Completed | Atezolizumab With Neoadjuvant Chemotherapy for Patients With Newly-Diagnosed Advanced-Stage Ovarian Cancer NCT03394885 | Duke University | Phase 1 / Phase 2 |
| Completed | Pharmacokinetic and Safety Study of Niraparib With Normal or Moderate Hepatic Impairment Patients NCT03359850 | Tesaro, Inc. | Phase 1 |
| Unknown | Pelvic Microbiomes of Benign and Malignant Ovarian Diseases NCT03388996 | Lei Li | — |
| Completed | A Study of Niraparib Combined With Bevacizumab Maintenance Treatment in Participants With Advanced Ovarian Can NCT03326193 | Tesaro, Inc. | Phase 2 |
| Terminated | Efficacy and Safety of PEG-rhG-CSF Secondary Prophylaxis vs. Therapeutic Administration in Patients With Ovari NCT03858166 | Shandong University | Phase 4 |
| Terminated | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physicia NCT02900248 | CureOne | — |
| Unknown | Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced a NCT03371693 | Zhongnan Hospital | Phase 3 |
| Unknown | EDMONd - Elemental Diet in Bowel Obstruction NCT03150992 | Royal Surrey County Hospital NHS Foundation Trust | N/A |
| Completed | Best Approach in Recurrent-Ovarian-Cancer-with Cediranib-Olaparib NCT03314740 | Mario Negri Institute for Pharmacological Research | Phase 2 |
| Unknown | Serum Biomarkers in Diagnosis and Predicting Prognosis of Ovarian Cancers NCT03112733 | Ilker Kahramanoglu | — |
| Unknown | Survival Outcomes of Ovarian Malignancies in Chinese Population NCT03291262 | Lei Li | — |
| Completed | Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in NCT02659384 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | Phase I Study of Cantrixil in Patients With Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer NCT02903771 | Kazia Therapeutics Limited | Phase 1 |
| Completed | Evaluating the Performance of Morphology Index in Surgical Decision-Making for Ovarian Tumors NCT02227654 | Frederick R. Ueland, M.D. | N/A |
| Unknown | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Muta NCT02950064 | Placon Therapeutics | Phase 1 |
| Completed | Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass. NCT02785731 | Angle plc | — |
| Active Not Recruiting | A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following NCT02655016 | Tesaro, Inc. | Phase 3 |
| Unknown | Improving Quality of Care for Patients With Recurrent Ovarian Cancer NCT02809339 | Radboud University Medical Center | — |
| Unknown | Intra-peritoneal Chemotherapy in Ovarian Cancer NCT02861872 | Radboud University Medical Center | — |
| Completed | Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Pres NCT02781272 | Angle plc | — |
| Completed | Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Rec NCT02751918 | Bayer | Phase 1 |
| Active Not Recruiting | Ovarian Cancer Hemoscope Trial NCT02811224 | Scripps Translational Science Institute | — |
| Completed | Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors NCT02658214 | AstraZeneca | Phase 1 |
| Terminated | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers NCT02711345 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or F NCT02903004 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 3 |
| Unknown | The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer NCT02687321 | Brno University Hospital | — |
| Completed | Efficacy and Safety Study of Pembrolizumab (MK-3475) in Participants With Advanced Recurrent Ovarian Cancer (M NCT02674061 | Merck Sharp & Dohme LLC | Phase 2 |
| Completed | Effect of Outpatient Symptom Management on Gynecologic Oncology Patients Receiving Chemotherapy NCT02786524 | University of Michigan | N/A |
| Completed | Use of Regorafenib in Recurrent Epithelial Ovarian Cancer NCT02736305 | National Cancer Centre, Singapore | Phase 2 |
| Terminated | Sentinel Node Detection in Ovarian Cancer NCT02540551 | Maastricht University Medical Center | Phase 1 |
| Terminated | Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors NCT02499952 | Nasser Hanna, M.D. | Phase 2 |
| Completed | The SOCQER-2 Study Surgery in Ovarian Cancer - Quality of Life Evaluation Research NCT02569983 | University of Birmingham | — |
| Unknown | Prospective Identification and Validation of "BRCANess" Profile in Ovarian Epithelial Cancer NCT02524808 | Fundación de investigación HM | — |
| Completed | Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Smal NCT02487095 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Unknown | DNA Single Nucleotide Polymorphisms as Predictors of Toxicity NCT02478476 | OvaGene Oncology, Inc. | — |
| Unknown | Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer NCT02494791 | University Health Network, Toronto | N/A |
| Completed | Biobehavioral Intervention in Gynecologic Oncology Patients NCT02454036 | Rachel Miller | Phase 2 |
| Terminated | AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant Ascites NCT02417753 | National Cancer Institute (NCI) | Phase 2 |
| Completed | MR-PET for Staging and Assessment of Operability in Ovarian Cancer - a Feasibility Study NCT02334371 | Maastricht University Medical Center | N/A |
| Recruiting | TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors NCT02429700 | Beihua Kong | Phase 3 |
| Completed | Guided Imagery in the Perioperative Period in Gynecologic Oncology Patients NCT02444195 | University of Michigan | N/A |
| Recruiting | TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors NCT02429687 | Beihua Kong | Phase 3 |
| Completed | A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Reg NCT02354586 | Tesaro, Inc. | Phase 2 |
| Active Not Recruiting | A Trial of Vigil for Participants With Ovarian Cancer NCT02346747 | Gradalis, Inc. | Phase 2 |
| Completed | Oncogenic Role of Engrailed (EN)-2 in Epithelial Ovarian Neoplasms NCT05553067 | Sohag University | — |
| Completed | The Canadian/US Integrative Oncology Study NCT02494037 | The Canadian College of Naturopathic Medicine | — |
| Unknown | Venous Thromboembolic Complications in Ovarian Cancer NCT02480790 | Ole Thorlacius-Ussing, MD, DMSc, Professor of Surgery | — |
| Completed | Cognitive-Existential Group Therapy to Reduce Fear of Cancer Recurrence: A RCT Study NCT03270995 | McGill University | N/A |
| Withdrawn | Magnetic Resonance Imaging for Lymph Node Staging in Ovarian Cancer NCT02243059 | Maastricht University Medical Center | Phase 4 |
| Terminated | PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer NCT02055690 | The Christie NHS Foundation Trust | Phase 1 / Phase 2 |
| Completed | STELLA 2 Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian C NCT02676726 | Hospital Universitari Vall d'Hebron Research Institute | N/A |
| Completed | A Study Evaluating the Safety and Pharmacokinetics of DMUC4064A in Participants With Platinum-Resistant Ovaria NCT02146313 | Genentech, Inc. | Phase 1 |
| Completed | Blood Collection From People With Ovarian Cancer NCT02063464 | National Cancer Institute (NCI) | — |
| Terminated | A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Bre NCT01905592 | Tesaro, Inc. | Phase 3 |
| Recruiting | DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics NCT02288676 | McGill University | — |
| Completed | Phase II Study DCVAC/OvCa Plus Carboplatin Gemcitabine Relapsed Platinum (Pt)-Sensitive Epithelial Ovarian Car NCT02107950 | SOTIO a.s. | Phase 2 |
| Completed | Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Ca NCT02107937 | SOTIO a.s. | Phase 2 |
| Completed | A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatme NCT01846611 | Janssen Research & Development, LLC | Phase 3 |
| Completed | Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pe NCT03193671 | Göteborg University | — |
| Terminated | A Study Of PF-06263507 In Patients With Advanced Solid Tumors NCT01891669 | Pfizer | Phase 1 |
| Terminated | Imaging Tumor Hypoxia With 18F-EF5 PET in Recurrent or Metastatic Clear Cell Ovarian Cancer NCT01881451 | British Columbia Cancer Agency | — |
| Completed | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer NCT01847274 | Tesaro, Inc. | Phase 3 |
| Completed | 89Zr-MMOT PET Imaging in Pancreatic and Ovarian Cancer Patients NCT01832116 | University Medical Center Groningen | Phase 1 |
| Withdrawn | 18F-CP18 Imaging Studies for Cancer Treatment With Birinapant NCT01766622 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Phase I Platinum Based Chemotherapy Plus Indomethacin NCT01719926 | UMC Utrecht | Phase 1 |
| Completed | A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer NCT01654458 | Women's College Hospital | N/A |
| Completed | A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer NCT01616303 | Quest PharmaTech Inc. | Phase 2 |
| Completed | STELLA Trial: Transperitoneal vs. Extraperitoneal Approach for Laparoscopic Staging of Endometrial/Ovarian Can NCT01810874 | Hospital Universitari Vall d'Hebron Research Institute | N/A |
| Unknown | Phase 3 Trial Evaluating Hyperthermic Intraperitoneal Chemotherapy in Upfront Treatment of Stage IIIC Epitheli NCT01628380 | A.O. Ospedale Papa Giovanni XXIII | Phase 3 |
| Recruiting | DOvEE - Diagnosing Ovarian & Endometrial Cancer Early NCT02296307 | McGill University | — |
| Completed | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Re NCT01478685 | Celgene | Phase 1 |
| Completed | Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients Wit NCT01462890 | AGO Study Group | Phase 3 |
| Completed | Efficacy,Tolerability,Safety of Temsirolimus in Women With Platinum-refractory Ovarian Carcinoma or Advanced E NCT01460979 | AGO Study Group | Phase 2 |
| Terminated | Amatuximab for High Mesothelin Cancers NCT01413451 | National Cancer Institute (NCI) | EARLY_Phase 1 |
| Completed | Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy NCT01384253 | Orano Med LLC | Phase 1 |
| Terminated | Dose Escalation Study of BIBF 1120 in Combination With Carboplatin and PLD in Relapsed Ovarian Cancer (OC) NCT01329549 | Boehringer Ingelheim | Phase 1 |
| Completed | BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallop NCT01314105 | Boehringer Ingelheim | Phase 1 |
| Unknown | Early Detection of Cancers in Low Resource Countries NCT01178736 | Woman's Cancer Foundation | — |
| Terminated | Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer NCT01279291 | Kyowa Kirin Co., Ltd. | Phase 1 |
| Withdrawn | A Prospective Trial of COXEN Chemotherapy Prediction NCT01228942 | University of Virginia | N/A |
| Completed | BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer NCT01121406 | Boehringer Ingelheim | Phase 2 |
| Completed | A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostat NCT01095848 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | Phase 1 |
| Completed | Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Ca NCT01313078 | National Cancer Institute (NCI) | Phase 2 |
| Completed | LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Tr NCT01015118 | Boehringer Ingelheim | Phase 3 |
| Terminated | A Study of the Safety and Pharmacokinetics of AGS-8M4 Given in Combination With Chemotherapy in Women With Ova NCT01016054 | Astellas Pharma Inc | Phase 1 |
| Terminated | Paclitaxel, Carboplatin and Vorinostat for the Treatment of Advanced Stage Ovarian Carcinoma NCT00976183 | Gynecologic Oncology Associates | Phase 1 / Phase 2 |
| Terminated | Cancer Screening Program for Women at High Risk for Developing Ovarian Cancer NCT01292733 | Swedish Medical Center | EARLY_Phase 1 |
| Completed | A Study of Liposomal Doxorubicin With or Without Olaratumab (IMC-3G3) in Platinum-Refractory or Resistant Adva NCT00913835 | Eli Lilly and Company | Phase 2 |
| Completed | A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors NCT00841191 | Centocor, Inc. | Phase 1 / Phase 2 |
| Terminated | Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Canc NCT00718523 | Translational Research in Oncology | Phase 2 |
| Completed | Study of AMG 479 as Second Line Therapy in Patients With Recurrent Platinum-sensitive Ovarian Cancer NCT00719212 | Translational Research in Oncology | Phase 2 |
| Completed | Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal NCT00791778 | Bayer | Phase 2 |
| Completed | A Phase 1 Study of the Safety and Pharmacokinetics of AGS-8M4 in Subjects With Advanced Ovarian Cancer NCT00816764 | Astellas Pharma Inc | Phase 1 |
| Completed | A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallo NCT00698451 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |
| Completed | Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian NCT00628251 | AstraZeneca | Phase 2 |
| Completed | AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer NCT00610714 | AstraZeneca | Phase 2 |
| Completed | Pharmacokinetic Study on the Administration of Nadroparin Dosing Serum HGF in Gynecological Patients NCT01523652 | Azienda Ospedaliera San Giovanni Battista | — |
| Completed | A Study to Determine the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ova NCT00746694 | Merck Sharp & Dohme LLC | — |
| Terminated | Efficacy Study of Additional Intraperitoneal Chemotherapy to Treat Ovarian Cancer NCT00919984 | Korea Cancer Center Hospital | Phase 2 |
| Completed | Safety and Efficacy of EGEN-001 Combined With Carboplatin and Docetaxel in Recurrent, Platinum-Sensitive, Ovar NCT00473954 | EGEN, Inc. | Phase 1 |
| Completed | Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer NCT00436657 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT00445549 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Pharmacogenomics of Paclitaxel in Ovarian Cancer NCT00415207 | University of Southern Denmark | — |
| Terminated | ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fal NCT00407407 | Celgene | Phase 1 |
| Completed | AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites NCT00396591 | Sanofi | Phase 2 |
| Completed | Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis NCT00243685 | Pierian Biosciences | Phase 2 / Phase 3 |
| Completed | Pharmacogenomics of Paclitaxel in Ovarian Cancer NCT00415181 | University of Southern Denmark | — |
| Completed | ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer NCT00325351 | Bayer | Phase 2 |
| Completed | Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symp NCT00327444 | Sanofi | Phase 2 / Phase 3 |
| Terminated | Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovari NCT00350948 | Telik | Phase 3 |
| Unknown | Tissue Bank of Biological Specimens From Patients With Gynecologic Disease NCT00299481 | U.S. Army Medical Research and Development Command | — |
| Completed | A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Ch NCT00710762 | Boehringer Ingelheim | Phase 2 |
| Completed | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas NCT00443196 | Pierian Biosciences | Phase 2 / Phase 3 |
| Unknown | Questionnaire Study for Gynecological Cancer Survivors NCT00391664 | U.S. Army Medical Research and Development Command | — |
| Completed | Diagnostic Imaging of Lymph Nodes in Gynaecologic Oncology NCT00288821 | UMC Utrecht | — |
| Completed | Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer NCT00246688 | Bayer | Phase 2 |
| Terminated | Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer NCT00137865 | EGEN, Inc. | Phase 1 |
| Completed | A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP) NCT00516373 | AstraZeneca | Phase 1 |
| Completed | Study of Pemetrexed in the Treatment of Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chem NCT00109096 | Eli Lilly and Company | Phase 2 |
| Completed | Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer NCT00130520 | University of Arizona | Phase 2 |
| Completed | Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia NCT00743431 | Merck Sharp & Dohme LLC | — |
| Completed | Microvascular Ultrasonographic Imaging for the Detection of Early Stage Epithelial Ovarian Carcinoma NCT00531570 | NYU Langone Health | — |
| Completed | Phase II Clinical Study of Pegylated Liposomal Doxorubicin Hydrochloride Injection as 2nd-line or Later Therap NCT00216645 | Janssen Pharmaceutical K.K. | Phase 2 |
| Completed | Acupuncture for Women's Health Conditions NCT00090389 | National Center for Complementary and Integrative Health (NCCIH) | Phase 1 |
| Completed | TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant NCT00102973 | Telik | Phase 3 |
| Completed | A Study to Evaluate Efficacy and Tolerance of Caelyx in Patients With Epithelial Ovarian Cancer. (Study P04072 NCT00727961 | Merck Sharp & Dohme LLC | Phase 4 |
| Completed | Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers NCT00231855 | Montefiore Medical Center | Phase 2 |
| Completed | An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation NCT00132704 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients NCT00127920 | Gynecologic Oncology Associates | Phase 2 |
| Completed | Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence NCT00123773 | AHS Cancer Control Alberta | Phase 2 |
| Completed | Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms NCT00160472 | United States Department of Defense | N/A |
| Recruiting | Establishment of a Tumor Bank for Blood Samples NCT01763125 | Medical University of Vienna | — |
| Completed | Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 To Treat Small-Volume Ovarian, Peritoneal, Fallopian Tub NCT00074867 | Pfizer | Phase 2 |
| Completed | Study of the Combination Carboplatin Plus Celecoxib in Heavily Pre-treated Recurrent Ovarian Cancer Patients NCT01124435 | Catholic University of the Sacred Heart | Phase 2 |
| Completed | Low Dose Upper Abdominal Radiation Therapy (LD-UART) + Gemcitabine in Patients With Advanced, Unresectable Pan NCT00390182 | University of Maryland, Baltimore | Phase 1 / Phase 2 |
| Completed | A Study to Evaluate the Safety and Efficacy of Caelyx in Combination With Carboplatin in Patients With Ovarian NCT00780039 | Merck Sharp & Dohme LLC | Phase 2 |
| Recruiting | Establishment of a Tumor Bank for Tissue Samples NCT01789229 | Medical University of Vienna | — |
| Completed | Efficacy and Safety of Subsequent Cisplatin and Docetaxel in Ovarian Cancer NCT00772863 | Sanofi | Phase 2 |
| Completed | Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer NCT00069160 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Biobehavioral-Cytokine Interactions in Ovarian Cancer NCT01113112 | Susan Lutgendorf | — |
| Completed | TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer NCT00057720 | Telik | Phase 3 |
| Unknown | Neoadjuvant Chemotherapy With Carboplatin and Docetaxel in Patients With Advanced Ovarian Cancer-Prospective, NCT00551577 | University Hospital, Bonn | Phase 2 |
| Completed | TAX + Carboplatin or Cisplatin 1st Line Post-Surgery Ovarian NCT00539669 | Sanofi | Phase 2 |
| Completed | TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer NCT00052065 | Telik | Phase 1 / Phase 2 |
| Completed | TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer NCT00051948 | Telik | Phase 1 / Phase 2 |
| Completed | OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers NCT00112086 | Japan Clinical Oncology Group | Phase 2 |
| Completed | A Study of Trabectedin in Patients With Advanced Ovarian Cancer NCT00050414 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 2 |
| Completed | An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemot NCT00191646 | Eli Lilly and Company | Phase 3 |
| Completed | Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer NCT00046800 | Astellas Pharma Inc | Phase 2 |
| Unknown | Study of T900607-Sodium in Previously Treated Patients With Ovarian Cancer. NCT00043446 | Tularik | Phase 2 |
| Completed | A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer. NCT00191607 | Eli Lilly and Company | Phase 3 |
| Terminated | A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carci NCT00034138 | Unither Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Docetaxel and Carboplatin as First-line Chemotherapy in Early Stage as Well as Advanced or Metastatic Ovarian NCT00452985 | Sanofi | — |
| Completed | EPO906 Therapy in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer NCT00035100 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer NCT00038428 | Telik | Phase 2 |
| Completed | Massage Therapy for Cancer-Related Fatigue NCT00039793 | National Center for Complementary and Integrative Health (NCCIH) | Phase 2 |
| Terminated | Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Car NCT00034372 | Unither Pharmaceuticals | Phase 2 |
| Recruiting | Institut Paoli Calmettes Ovarian Cancer Database NCT02869568 | Institut Paoli-Calmettes | — |
| Completed | Breast Cancer in Poland: An Expanded Study to Assess Occupational and Environmental Factors and Interactions W NCT00341458 | National Cancer Institute (NCI) | — |
| Terminated | CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Pl NCT00653952 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Phase 3 |
| Unknown | Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers NCT00178802 | The University of Texas Health Science Center, Houston | Phase 2 |
| Completed | Outcomes of Education and Counseling for BRCA1 Testing NCT00001468 | National Human Genome Research Institute (NHGRI) | — |
| Completed | A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin With G-CSF Support in Patients With NCT00001427 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ascertainment of Peripheral Blood or Saliva Samples for Genetic Epidemiology Studies of Familial Cancers NCT00579163 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | KOrean Borderline Ovarian Tumor (KOBOT) Registry NCT02803970 | Kangbuk Samsung Hospital | — |
| Completed | A Phase I Study of Taxol, Cisplatin, Cyclophosphamide and Granulocyte Colony-Stimulating Factor (G-CSF) in Pre NCT00001272 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer NCT00120939 | Pharmacyclics LLC. | Phase 1 |
| Unknown | A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies NCT00057395 | Aronex Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors NCT00080041 | Pharmacyclics LLC. | Phase 1 |
| Terminated | Safety/Efficacy Study of SGN-15 (Antibody-Drug Conjugate) Combined With Gemcitabine in Patients With Ovarian C NCT00051584 | Seagen Inc. | Phase 2 |